Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is one of the best low-priced pharma stocks on this list.

TheFly reported on June 11 that XERS announced that the USPTO issued a notice of allowance for U.S. Patent Application No. 17/151,405, covering compositions and methods of use related to its Keveyis product. The allowed claims were determined to meet patentability requirements and are expected to advance toward patent issuance after completing standard administrative procedures. Following approval, Xeris plans to submit the patent for inclusion in the FDA’s Orange Book listing. If issued and maintained through required filings and fees, the new patent is expected to extend intellectual property protection for Keveyis through 2039.

Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?

Simultaneously, on June 11, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) entered into privately negotiated exchange agreements with holders of its 8.00% Convertible Senior Notes due 2028. Under the agreements, the company plans to retire approximately $23 million in principal amount of notes through a combination of cash payments and common stock issuance. The number of shares issued will depend on the volume-weighted average trading price of XERS common stock during a 21-day averaging period beginning June 11. Based on an assumed average price of $6.71, XERS expects to issue about 4.6 million shares. After completion, approximately $10.5 million of notes will remain outstanding.

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a commercial-stage biopharmaceutical company developing ready-to-use, room-temperature stable therapies for endocrine and neurological disorders.

While we acknowledge the risk and potential of XERS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than XERS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1